The Journal of Experimental Medicine
StemCell Technologies
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 16 October 2000.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kovalchuk, A. L.
Right arrow Articles by Morse, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kovalchuk, A. L.
Right arrow Articles by Morse, H. C., , III
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2000/10/1183/ $5.00
The Journal of Experimental Medicine, Volume 192, Number 8, October 16, 2000 1183-1190

Brief Definitive Report

Burkitt Lymphoma in the Mouse

Alexander L. Kovalchuka, Chen-Feng Qib, Ted A. Torreyb, Lekidelu Taddesse-Heathb, Lionel Feigenbaumc, Sung Sup Parka, Armin Gerbitzd, Gustav Klobecke, Konstanze Hoertnageld, Axel Polackd, Georg W. Bornkammd, Siegfried Janza, and Herbert C. Morse, IIIb
a Laboratory of Genetics, National Cancer Institute,
b Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
c Science Applications International Corporation (SAIC), Frederick Cancer Research Center, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702
d Institut für Klinische Molekularbiologie und Tumorgenetik, Munich 81377, Germany
e Institut für Physiologische Chemie der Ludwig-Maximilian Universität, Munich 80336, Germany

Correspondence to: Herbert C. Morse, III, LIP, NIAID, 7 Center Dr., Rm. 7/304, MSC 0760, Bethesda, MD 20892-0760. Tel:301-496-6379 Fax:301-402-0077

Chromosomal translocations juxtaposing the MYC protooncogene with regulatory sequences of immunoglobulin (Ig) H chain or kappa (Ig{kappa}) or lambda (Ig{lambda}) L chain genes and effecting deregulated expression of MYC are the hallmarks of human Burkitt lymphoma (BL). Here we report that lymphomas with striking similarities to BL develop in mice bearing a mutated human MYC gene controlled by a reconstructed Ig{lambda} locus encompassing all the elements required for establishment of locus control in vitro. Diffusely infiltrating lymphomas with a typical starry sky appearance occurred in multiple founders and an established line, indicating independence from positional effects. Monoclonal IgM+CD5-CD23- tumors developed from an initially polyclonal population of B cells. These results demonstrate that the phenotype of B lineage lymphomas induced by MYC dysregulation is highly dependent on cooperativity among the regulatory elements that govern expression of the protooncogene and provide a new system for studying the pathogenesis of BL.

Key Words: Burkitt lymphoma, locus control region, mouse lymphoma, MYC, translocation


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS